Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration 
Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support 
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change 
Starlink Plans Satellite Orbit Reconfiguration in 2026 to Boost Space Safety 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
Bain Capital Moves to Acquire Majority Stake in Echo Marketing 
Neuralink Plans Automated Brain Implant Surgeries and Mass Production by 2026 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026 
Drugmakers Plan 2026 U.S. Price Increases on Over 350 Branded Medications Despite Political Pressure 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Lockheed Martin Secures $328.5 Million U.S. Defense Contract for Advanced Systems Supporting Taiwan Air Force 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
ALISO VIEJO, Calif., March 09, 2017 -- NVISION Eye Centers – a national leader in ophthalmic treatments and services, is pleased to announce the introduction of Avedro Photrexa® Viscous, Photrexa® and the KXL System used in corneal collagen cross-linking for the treatment of keratoconus. The procedure has the ability to both stabilize and strengthen the cornea, halting or slowing the progression of keratoconus in the early phases of the condition. It can also improve vision in some patients with a more progressed stage of the condition.
“Keratoconus is a progressive thinning and distortion of the cornea that can result in significant visual loss and may lead to the need for a corneal transplant.” states Dr. Tom Tooma, founder of NVISION Eye Centers. “NVISION surgeons are treating patients who are suffering from progressive keratoconus. We are excited to offer a long term solution to our patients with this condition.”
The announcement follows the recent approval that Avedro, Inc., an ophthalmic pharmaceutical and medical device company, has received from the U.S. Food and Drug Administration (FDA).
ABOUT NVISION EYE CENTERS: NVISION Eye Centers is one of the largest providers of LASIK and cataract surgery in the U.S., with 26 centers in California, Nevada, Oregon, Arizona and Toronto, Canada. An innovative leader in ophthalmology, NVISION is dedicated to providing the best patient experience through the use of the latest technology and treatment by the most talented and experienced surgeons in the industry. NVISION was founded in 2010 by Tom Tooma, M.D., one of the earliest pioneers of LASIK who has performed more than 100,000 procedures throughout his esteemed career. With more than 1,900 eye doctors referring their patients and trusting their own eyes to NVISION surgeons, NVISION Eye Centers is the Eye Doctors' #1 Choice®. For more information, visit www.NVISIONCenters.com or call (877) 455-9942.
